The report entitled “The US Onychomycosis Market (2018 Edition)”, provides analysis of the US onychomycosis market, with detailed analysis of market size and growth, market share and economic impact of the industry. The analysis includes the market by value, by volume and by segments. The report also includes the detailed analysis of the segments of the onychomycosis market, comprising of market by value, by volume and by average prices.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/2327573
In addition to this, a global analysis of the overall skin infections drugs market in terms of value followed by analysis of drugs used for the treatment of onychomycosis type of skin infection such as Kerydin and Jublia in terms of value has been done in this report.
Valeant Pharmaceuticals, Pfizer, Inc., Novartis AG and Johnson & Johnson are some of the key players operating in the US onychomycosis market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.
Johnson & Johnson
Onychomycosis is a condition of fungal nail infection. Onychomycosis begins in the nail bed and progresses to the nail plate, causing the nail to become discolored, deformed, and even separated from the nail bed. Onychomycosis has a significant chance of reoccurrence. Of all the nail abnormalities in the world, around 50% are the case of onychomycosis. In most of the cases it occurs in the toenails. Onychomycosis is not a life threatening disease but, may persist or worsen if not treated.
Symptoms of onychomycosis are changes in appearance of the nail, interference with standing, walking, and exercising, pain, discomfort, etc. The causative pathogens of onychomycosis include dermatophytes (most common), Candida, and nondermatophytic molds.
There are five types of Onychomycosis: Distal Subungual Onychomycosis, White superficial onychomycosis, Proximal subungual onychomycosis, Endonyx onychomycosis and Candidal onychomycosis. Two types of treatments are available of onychomycosis: Oral Treatment and Topical Treatment. Oral treatment includes: Terbinafine, Itraconazole, etc. and topical treatment includes Kerydin, Jublia, etc. Nonpharmacologic approaches are also there, which includes the following: Laser treatment, Photodynamic therapy, etc.
The US onychomycosis market (prescription drugs) has increased with a healthy growth rate over the years and is expected to increase further during the forecasted period. The US onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.
Browse the complete report @ http://www.orbisresearch.com/reports/index/the-us-onychomycosis-market-size-trends-and-forecasts-2018-edition
Some Points from Table of Content:
- Executive Summary
2.1 Onychomycosis: An Overview
2.1.1 Signs and Symptoms
2.1.2 Causes of Onychomycosis
2.2 Types of Onychomycosis
2.3 Treatment For Onychomycosis
- Global Market Analysis
3.1 Global Skin Infections Drugs Market: An Analysis
3.1.1 Global Skin Infections Drugs Market by Value
3.1.2 Global Skin Infections Drugs Market by Products (Drugs for Onychomycosis and Other Skin Infection Drugs)
3.2 Global Onychomycosis Market: Product Analysis
3.2.1 Global Kerydin Drugs Market by Value
3.2.2 Global Jublia Drugs Market by Value
3.3 Global Onychomycosis Market: Pipeline Drugs Analysis
3.3.1 Global Skin Infection Market- Phase II Drugs (Onychomycosis) Pipeline Forecast
3.3.2 Global Skin Infection Market- Phase III Drugs (Onychomycosis) Pipeline Forecast
3.4 Onychomycosis Market: New Drugs Overview
- US Market Analysis
4.1 The US Nail Care Market: An Analysis
4.1.1 The US Nail Care Market by Value
4.1.2 The US Nail Care Market by Segments (Jublia and Other Generic Drugs Including Kerydin)
4.2 The US Nail Care Market: Segment Analysis
4.2.1 The US Jublia Drug Market by Value
4.2.2 The US Jublia Drug Market by Volume
4.2.3 The US Kerydin Drug Market by Value
4.2.4 The US Kerydin Drug Market by Volume
4.2.5 The US Generic Drugs Market by Value
4.3 The US Onychomycosis Market: An Analysis
4.3.1 The US Onychomycosis Market by Prevalence
4.3.2 The US Onychomycosis Market Prevalence by Segments
- Competitive Landscape
5.1 Competition in Onychomycosis Prescription Market: An Overview
5.2 Financial Comparison of Major Players of the US Onychomycosis Market
- Company Profiles
6.1 Valeant Pharmaceuticals
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy
6.3 Johnson & Johnson
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy
6.4 Novartis AG
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy
Make an enquiry of this report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/2327573
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019